Showing 15 posts of 343 posts found.

Merck’s Keytruda approved by EC for gastric cancer

August 30, 2023
Research and Development EC, Merck, Oncology, gastric cancer, keytruda

Merck (known as MSD outside of the US and Canada) has announced the approval of its gastric cancer treatment, Keytruda, …

Lynparza granted approval to treat prostate cancer in Japan

August 25, 2023
Research and Development Merck, Oncology, astra zeneca, prostate cancer

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …

Merck announces phase 3 LITESPARK-005 trial met primary endpoint

August 22, 2023
Research and Development Merck, Oncology, Welireg, belzutifan, clinical trial, renal cell carcinoma

Merck (known as MSD outside of the US and Canada) has shared topline results from its phase 3 LITESPARK-005 trial, …

Astex expands collaboration with MSD

August 8, 2023
Business Services Astex pharmaceuticals, Merck, Oncology, collaboration, small molecules

Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with MSD (known as Merck in the US), …


Merck shares data from phase 3 trial for breast cancer treatment

August 1, 2023
Research and Development MSD, Merck, Oncology, breast cancer, keytruda

Merck, also known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-756 …

Merck invests €35m in biosafety testing in Scotland

May 31, 2023
Manufacturing and Production Merck, biosafety, drug development, testing

Merck has announced that it has invested €35m in biosafety testing at its sites in Glasgow and Stirling, both Scotland. …

NICE rejects Merck Serono’s Bavencio for urothelial cancer

May 10, 2021
Sales and Marketing MSD, Merck, NHS, NICE, cancer treatment, pharma, pharma news

The use of avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy is not recommended by …

Merck kidney and uterus cancer treatments granted priority review by FDA

May 7, 2021
Medical Communications FDA, MSD, Merck, cancer treatment, kidney cancer treatment, pharma, pharma news, uterus cancer treatment

The FDA has granted priority review for Merck (MSD) and Eisai’s application for two new approvals for the combination of …

Merck cease development of $425 million COVID-19 treatment

April 16, 2021
Medical Communications COVID-19, MSD, Merck, covid-19 treatment, pharma, pharma news

Merck (MSD) have ended the development of their MK-7110 drug for the treatment of hospitalised patients with COVID-19.

Merck and UCLA find new COVID-19 treatment candidate

March 25, 2021
COVID-19, Merck, berzosertib, covid-19 treatment, ucla

Merck (MSD in the UK), the UCLA, and other universities from the US and Germany have uncovered a compound that …


NHS England increases access to cladribine tablets for multiple sclerosis patients during pandemic

March 3, 2021
Research and Development Cladribine, Mavenclad, Merck, multiple sclerosis

NHS England has updated the Blueteq requirements for patients with highly active relapsing MS starting Merck’s cladribine (Mavenclad) tablets during …

Merck building

Merck and Debiopharm agree €898m deal to develop head and neck cancer treatments

March 1, 2021
Sales and Marketing Debiopharm, Merck, cancer treatment, head and neck cancer, xevinapant

German science and technology company Merck have agreed a worldwide in-licensing agreement with Debiopharm for the development and commercialisation of …


Merck, Pfizer, and 4D pharma join forces for bladder cancer clinical trial

February 8, 2021
Sales and Marketing Cancer, Merck, Pfizer

A clinical trial collaboration between 4D pharma, Merck, and Pfizer to treat locally advanced or metastatic urothelial carcinoma (UC), also …


MSD discontinues development of COVID-19 vaccines

January 26, 2021
Manufacturing and Production MSD, Merck

Merck, known as MSD outside of the US and Canada, has announced that the company is discontinuing development of its …


Pfizer and Merck KGaA secure CHMP recommendation for Bavencio in Europe for first-line maintenance of urothelial carcinoma

December 14, 2020
Sales and Marketing Bavencio, CHMP, EMA, Merck, Pfizer, pharma, urothelial carcinoma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given its recommendation for …

Latest content